

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

# SAFETY DATA SHEET

FRS-40 SEMI-GLOSS BASE 3 BEIGE MAPPLE / A314

## SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product ident	tifier
-------------------	--------

Product name SDS code : FRS-40 SEMI-GLOSS BASE 3 BEIGE MAPPLE / A314 : 4092A314B

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

	Identified uses
Paint. Professional us	e Industrial use
	Uses advised against
All other uses	
Product use	: Solvent borne coating for interior use.

#### 1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex France e-mail address of person : PSRA PAMIERS@akzonobel.com

#### 1.4 Emergency telephone number

responsible for this SDS

National advisory body/Pois	<u>son Center</u>	
Telephone number	: +44 (0)344 892 011	1
<u>Supplier</u>		
Telephone number	: +33 (0)5 34 01 34 0 +33 (0)5 61 60 23 3	
Hours of operation	+33 (0)5 01 00 23 3 :	U

## **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

Product definition : Mixture

#### Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H336 STOT RE 2, H373

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	1/19	AkzoNobel

## **SECTION 2: Hazards identification**

See Section 11 for more detailed information on health effects and symptoms.

2

#### 2.2 Label elements

Hazard pictograms



Signal word	:	Warning
Hazard statements	:	Flammable liquid and vapor. Causes skin irritation. Causes serious eye irritation. May cause drowsiness or dizziness. May cause damage to organs through prolonged or repeated exposure.
Precautionary statements		
Prevention	:	Wear protective gloves. Wear eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Do not breathe vapor. Wash hands thoroughly after handling.
Response	:	Get medical advice or attention if you feel unwell. IF INHALED: Call a POISON CENTER or doctor if you feel unwell. Take off contaminated clothing and wash it before reuse. IF ON SKIN: Wash with plenty of water. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention.
Storage	:	Store in a well-ventilated place. Keep container tightly closed. Keep cool.
Disposal	:	Dispose of contents and container in accordance with all local, regional, national and international regulations.
Hazardous ingredients	:	<ul> <li>butyl acetate</li> <li>Reaction mass of ethylbenzene and xylene</li> <li>2-methoxy-1-methylethyl acetate</li> </ul>
Supplemental label elements	:	Contains methyl methacrylate. May produce an allergic reaction. Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	Not applicable.
Special packaging requirem	en	ts
Containers to be fitted with child-resistant fastenings	:	Not applicable.
Tactile warning of danger	:	Not applicable.
2.3 Other hazards		
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	:	None known.

Product/ingredient name	Identifiers	%	Regulation (EC) No. 1272/2008 [CLP]	Туре
p-butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1	≥10 - ≤15	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	[1] [2]
Reaction mass of ethylbenzene and xylene	REACH #: 01-2119488216-32	≥10 - <20	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
2-methoxy-1-methylethyl acetate	REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6	≤10	Flam. Liq. 3, H226 STOT SE 3, H336	[1] [2]
methyl methacrylate	REACH #: 01-2119452498-28 EC: 201-297-1 CAS: 80-62-6 Index: 607-035-00-6	≤0.3	Flam. Liq. 2, H225 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335	[1] [2]
cyclohexanone	REACH #: 01-2119453616-35 CAS: 108-94-1 Index: 606-010-00-7	≤0.3	Flam. Liq. 3, H226 Acute Tox. 4, H332	[1] [2]
Hydrocarbons, C11-C14, n- alkanes, isoalkanes, cyclics, <2% aromatics	REACH #: 01-2119456620-43 EC: 926-141-6	≤0.2	Asp. Tox. 1, H304 EUH066	[1]
			See Section 16 for the full text of the H statements declared above.	

## **SECTION 3: Composition/information on ingredients**

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

<u>Type</u>

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII

[4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

[5] Substance of equivalent concern

[6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.



### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

Eye contact	:	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
Inhalation	:	Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Skin contact	:	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	:	Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	:	No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

#### 4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains methyl methacrylate. May produce an allergic reaction.

#### Over-exposure signs/symptoms

Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness



## SECTION 4: First aid measures

Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	<ul> <li>Adverse symptoms may include the following: irritation redness</li> </ul>
Ingestion	: No specific data.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	<ul> <li>Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.</li> </ul>
Specific treatments	: No specific treatment.

## **SECTION 5: Firefighting measures**

	5
5.1 Extinguishing media	
Suitable extinguishing media	: Use dry chemical, CO <sub>2</sub> , water spray (fog) or foam.
Unsuitable extinguishing media	: Do not use water jet.
5.2 Special hazards arising	from the substance or mixture
Hazards from the substance or mixture	: Flammable liquid and vapor. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion.
Hazardous combustion products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide halogenated compounds metal oxide/oxides
5.3 Advice for firefighters	
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

## **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel	: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.		
For emergency responders	<ul> <li>If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".</li> </ul>		
Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	5/19	AkzoNobel

#### **SECTION 6: Accidental release measures**

6.2 Environmental precautions	:	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).			
6.3 Methods and materials for	or c	ontainment and cleaning up			
Small spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.			
Large spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product.			
6.4 Reference to other sections	:	See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.			

## **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Do not breathe vapor or mist. Do not ingest. Avoid contact with eyes, skin and clothing. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

#### Seveso Directive - Reporting thresholds

#### Danger criteria

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	6/19	AkzoNobel

S	SECTION 7: Handling and storage					
		Notification and MAPP threshold	Safety report threshold			
	P5c	5000 tonne	50000 tonne			

#### 7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific solutions	: Not available.

## **SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

#### 8.1 Control parameters

#### **Occupational exposure limits**

Product/ingredient name	Exposure limit values
r −butyl acetate	EH40/2005 WELs (United Kingdom (UK), 1/2020). STEL: 966 mg/m <sup>3</sup> 15 minutes. STEL: 200 ppm 15 minutes. TWA: 724 mg/m <sup>3</sup> 8 hours. TWA: 150 ppm 8 hours.
Reaction mass of ethylbenzene and xyle	
2-methoxy-1-methylethyl acetate	EH40/2005 WELs (United Kingdom (UK), 8/2018). Absorbed through skin. STEL: 548 mg/m <sup>3</sup> 15 minutes. TWA: 50 ppm 8 hours. TWA: 274 mg/m <sup>3</sup> 8 hours. STEL: 100 ppm 15 minutes.
methyl methacrylate	EH40/2005 WELs (United Kingdom (UK), 1/2020). STEL: 416 mg/m <sup>3</sup> 15 minutes. STEL: 100 ppm 15 minutes. TWA: 208 mg/m <sup>3</sup> 8 hours. TWA: 50 ppm 8 hours.
cyclohexanone	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed through skin. STEL: 20 ppm 15 minutes. TWA: 10 ppm 8 hours. STEL: 82 mg/m <sup>3</sup> 15 minutes. TWA: 41 mg/m <sup>3</sup> 8 hours.
procedures atmosp of the v protection the follow the ass limit value atmosp of exponent (Workp	roduct contains ingredients with exposure limits, personal, workplace here or biological monitoring may be required to determine the effectiveness entilation or other control measures and/or the necessity to use respiratory ve equipment. Reference should be made to monitoring standards, such as owing: European Standard EN 689 (Workplace atmospheres - Guidance for essment of exposure by inhalation to chemical agents for comparison with lues and measurement strategy) European Standard EN 14042 (Workplace heres - Guide for the application and use of procedures for the assessment sure to chemical and biological agents) European Standard EN 482 lace atmospheres - General requirements for the performance of procedures measurement of chemical agents) Reference to national guidance
Date of issue/Date of revision : 1-11-2	
Date of previous issue : 1-10-2	022 7/19 AkzoNobel

### **SECTION 8: Exposure controls/personal protection**

documents for methods for the determination of hazardous substances will also be required.

#### **DNELs/DMELs**

NormalNormal DNELLong term Dermal DWdayBwday Seneral populationSeneral populationSDNELLong term Dermal Inhalation12 mg/m2 PopulationGeneral populationSDNELLong term Inhalation12 mg/m2 InhalationGeneral populationSDNELLong term Inhalation48 mg/m2WorkersSDNELLong term Inhalation102.34 mg/ populationGeneral populationLDNELLong term Inhalation48 mg/m2General populationLDNELShort term Inhalation659.7 mg/ populationGeneral populationSDNELShort term Inhalation859.7 mg/ populationGeneral populationSDNELShort term Inhalation960 mg/m3WorkersLDNELShort term Inhalation960 mg/m3WorkersSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term 	Effects	Population	Value	Exposure	Туре	Product/ingredient name
DNELLong term Dermal3.4 mg/mgGeneralS.DNELLong term Dermal7 mg/kgWorkersS.DNELLong term12 mg/m³GeneralS.DNELLong term12 mg/m³GeneralS.DNELLong term102.34 mg/GeneralL.DNELLong term102.34 mg/GeneralL.DNELLong term148 mg/m³WorkersL.DNELLong term480 mg/m³WorkersL.DNELLong term480 mg/m³WorkersL.DNELLong term480 mg/m³WorkersL.DNELShort term859.7 mg/GeneralL.Inhalationm³populationS.DNELShort term960 mg/m³WorkersS.DNELShort term960 mg/m³WorkersS.DNELLong term1.6 mg/kgGeneralS.populationDNELLong term Dermal1.6 mg/kgGeneralS.populationDNELLong term Dermal180 mg/kgGeneralS.populationDNELLong term Dermal180 mg/kgGeneralS.populationDNELLong term Dermal180 mg/kgGeneralS.populationDNELLong term Dermal180 mg/kgWorkersS.populationDNELLong term Dermal180 mg/kgWorkersS.populationDNELLong term Dermal180 mg/kgWorkers <td< td=""><td>Systemic</td><td></td><td></td><td>Long term Oral</td><td>DNEL</td><td>n-butyl acetate</td></td<>	Systemic			Long term Oral	DNEL	n-butyl acetate
NetLong term Dermal bw/daybw/day WorkersSDNELLong term12 mg/m² bw/dayGeneral generalSDNELLong term148 mg/m²WorkersSInhalationInhalationm²General populationLDNELLong term102.34 mg/ populationGeneral populationLDNELLong term102.34 mg/ populationGeneral populationLDNELLong term162.34 mg/ populationGeneral populationLDNELShort term859.7 mg/ populationGeneral populationLDNELShort term960 mg/m²WorkersLInhalationm² inhalationBS9.7 mg/ populationGeneral populationLDNELShort term960 mg/m²WorkersSInhalationInhalation16 mg/kg populationGeneral populationSDNELLong term17.6 mg/kg bw/dayGeneral populationSDNELLong term108 mg/kg bw/dayGeneral populationSDNELLong term108 mg/kg bw/dayGeneral populationSDNELLong term108 mg/kg bw/dayGeneral populationSDNELLong term108 mg/kg bw/dayGeneral populationSDNELLong term108 mg/kg bw/dayGeneral populationSDNELLong term104 mg/m² gopulationGeneral populationS <t< td=""><td></td><td></td><td></td><td></td><td><b></b></td><td></td></t<>					<b></b>	
DNELLong term Dermal7 mg/kg bw/dayWorkersS populationDNELLong term12 mg/m² inhalationGeneral populationS populationS populationDNELLong term102.34 mg/ inhalationGeneral populationLong populationLong inhalationI m²DNELLong term480 mg/m² inhalationGeneral populationLong inhalationLong inhalationLong inhalationMorkersLong inhalationDNELShort term859.7 mg/ inhalationGeneral m² populationS populationS populationS populationDNELShort term960 mg/m² inhalationWorkersL inhalationS populationS populationS populationDNELShort term960 mg/m² inhalationWorkersS inhalationS populationS populationS populationDNELLong term Oral1.6 mg/kg bw/dayGeneral populationS populationS populationS populationDNELLong term Dermal inhalation108 mg/kg bw/dayGeneral populationS populationS populationDNELLong term Dermal inhalation108 mg/kg bw/dayGeneral populationS populationS populationDNELLong term Dermal inhalation108 mg/kg bw/dayGeneral populationS populationS populationDNELLong term Dermal inhalation104 mg/m² populationGen	Systemic			Long term Dermal	DNEL	
methyl methacrylate         DNEL         Long term         12 mg/m <sup>3</sup> General population         S           DNEL         Long term         48 mg/m <sup>3</sup> Workers         S           DNEL         Long term         48 mg/m <sup>3</sup> Workers         L           DNEL         Long term         102.34 mg/         General population         L           DNEL         Long term         480 mg/m <sup>3</sup> Workers         L           Inhalation         m <sup>3</sup> Workers         L         Inhalation         m <sup>3</sup> population           DNEL         Short term         859.7 mg/         General population         population         D           DNEL         Short term         960 mg/m <sup>3</sup> Workers         L         Inhalation         m <sup>3</sup> population         D           DNEL         Short term         960 mg/m <sup>3</sup> Workers         S         Inhalation         D						
DNEL Inhalation Inhalation12 mg/m³ opulation populationGeneral populationSDNEL Inhalation Inhalation00.2.34 mg/m³ WorkersGeneral populationLDNEL Inhalation102.34 mg/m³ WorkersGeneral populationLDNEL Inhalation102.34 mg/m³ WorkersGeneral populationLDNEL InhalationSb9.7 mg/ BopulationGeneral populationLDNEL InhalationShort term Inhalation859.7 mg/ BopulationGeneral populationLDNEL InhalationShort term Inhalation860 mg/m³ WorkersWorkersLDNEL InhalationShort term Inhalation960 mg/m³ WorkersWorkersLDNEL InhalationDNEL InhalationI.6 mg/kg BopulationGeneral populationSDNEL InhalationDNEL InhalationI.6 mg/kg BopulationGeneral SSDNEL InhalationDNEL InhalationI.6 mg/kg BopulationGeneral SSDNEL InhalationDNEL InhalationCaneral Bow/daySDNEL InhalationDNEL InhalationSWorkersSDNEL InhalationDNEL InhalationSGeneral Bow/daySDNEL InhalationDNEL InhalationSGeneral Bow/daySDNEL InhalationDNEL InhalationSGeneral Bow/daySDNEL InhalationDNEL InhalationCaneral Bow/dayS	Systemic	Workers		Long term Dermal	DNEL	
Inhalation DNEL Long termpopulation 48 mg/m³population Workerspopulation S S InhalationDNEL InhalationLong term102.34 mg/ opoulationGeneral populationL InhalationDNEL InhalationLong term480 mg/m³WorkersL InhalationDNEL InhalationDNEL InhalationS9.7 mg/ GeneralGeneral populationL InhalationDNEL InhalationShort term859.7 mg/ GeneralGeneral populationL InhalationDNEL InhalationShort term960 mg/m³ WorkersWorkersL InhalationDNEL InhalationShort term960 mg/m³ WorkersWorkersS InhalationDNEL InhalationDNEL Inhalation1.6 mg/kg populationGeneral populationS populationDNEL InhalationDNEL InhalationIng general populationS populationS populationS populationDNEL InhalationLong term Dermal Inhalation1.6 mg/kg populationGeneral populationS populationDNEL InhalationDNEL InhalationInhalation InhalationNorkersS populationDNEL InhalationDNEL InhalationIo8 mg/kg bw/dayWorkersS populationDNEL InhalationDNEL InhalationIo8 mg/kg bw/dayGeneral populationS populationDNEL InhalationDNEL InhalationIo8 mg/kg bw/dayGeneral populationS population <tr< td=""><td></td><td></td><td></td><td></td><td></td><td></td></tr<>						
DNEL Inhalation InhalationLong term inhalation48 mg/m³WorkersSDNEL Inhalation DNELLong term Inhalation102.34 mg/ populationGeneral populationLDNEL InhalationDNEL InhalationS9.7 mg/ GeneralGeneral populationLDNEL InhalationShort term B59.7 mg/ GeneralGeneral populationLDNEL InhalationShort term B60 mg/m³General WorkersLDNEL InhalationShort term Inhalation960 mg/m³ WorkersWorkersSDNEL InhalationDNEL InhalationShort term populationGeneral populationSDNEL InhalationDNEL InhalationI.6 mg/kg Bord/ayGeneral populationSDNEL InhalationDNEL InhalationI.6 mg/kg Bord/ayGeneral populationSDNEL InhalationDNEL InhalationI08 mg/kg Bw/dayGeneral populationSDNEL InhalationDNEL Inhalation108 mg/kg Bw/dayGeneral populationSDNEL InhalationDNEL InhalationSMorkersSDNEL InhalationDNEL InhalationSMorkersSDNEL InhalationLong term Dermal Inhalation8.2 mg/kg BorkersGeneral populationSDNEL InhalationDNEL InhalationSGeneral populationGeneral populationSDNEL InhalationIng term Inhalation104 mg/m³ Bo	Systemic		12 mg/m³		DNEL	
Inhalation Inhalation00DNEL InhalationLong term Inhalation102.34 mg/ populationGeneral populationLong termDNEL InhalationNet InhalationSbo.7 mg/ m³General GeneralLong termDNEL InhalationSbo.7 term m³859.7 mg/ WorkersGeneral GeneralLong termDNEL InhalationSbort term Inhalation859.7 mg/ WorkersGeneral WorkersLong General populationDNEL InhalationDNEL InhalationSbort term Boom g/m³WorkersLong General populationDNEL InhalationDNEL InhalationLong term DNEL Inhalation1.6 mg/kg Boreral populationSongeral Songeral Songeral WorkersS Songeral Songeral WorkersS Songeral Songeral WorkersS Songeral Songeral Songeral WorkersS Songeral Songeral Songeral WorkersS Songeral Songeral Songeral WorkersS Songeral Songeral Songeral Songeral Songeral Songeral WorkersS Songeral <br< td=""><td></td><td></td><td></td><td></td><td></td><td></td></br<>						
DNELLong term Inhalation102.34 mg/ m³General populationLi populationDNELLong term Inhalation480 mg/m³WorkersLi populationLi populationLi populationDNELShort term Inhalation859.7 mg/ m³General populationLi populationLi populationLi populationDNELShort term Inhalation960 mg/m³WorkersLi populationLi populationLi populationDNELShort term Inhalation960 mg/m³WorkersSDNELShort term Inhalation960 mg/m³WorkersSDNELShort term Inhalation960 mg/m³WorkersSDNELLong term Oral Inhalation1.6 mg/kg bw/dayGeneral populationSDNELLong term Oral Inhalation1.6 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSmethyl methacrylateDNELLong term Dermal Inhalation828 mg/m³WorkersSDNELLong term Dermal Inhalation208 mg/m³WorkersSDNELLong term Dermal Inhalation208 mg/m³WorkersSDNELLong term Dermal Inhalation208 mg/m³WorkersSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral <b< td=""><td>Systemic</td><td>Workers</td><td>48 mg/m³</td><td></td><td>DNEL</td><td></td></b<>	Systemic	Workers	48 mg/m³		DNEL	
Inhalationm³populationDNELLong term480 mg/m³WorkersLiInhalation859.7 mg/ populationGeneral GeneralLiDNELShort term859.7 mg/ populationGeneral GeneralSDNELShort term960 mg/m³WorkersLiInhalationm³m9WorkersLiInhalationm3WorkersLiDNELShort term960 mg/m³WorkersSInhalation1.6 mg/kgBeneral populationSDNELLong term14.8 mg/m³General populationSpopulationDNELLong term17 mg/m³General populationSDNELLong term108 mg/kg bw/dayBeneral populationSDNELLong termDRELLong term108 mg/kg bw/dayBeneral populationSDNELLong termDRELLong term289 mg/m³WorkersSInhalationDNELLong term289 mg/m³WorkersSInhalationDNELLong term104 mg/m³General populationSDNELLong term104 mg/m³General populationSDNELLong term104 mg/m³General populationSDNELLong term208 mg/m³WorkersSInhalationDNELLong term208 mg/m³General populationSDNELLong term208 mg/m³General populatio						
DNEL InhalationLong term Inhalation480 mg/m³WorkersLink General populationDNEL InhalationDNEL Short term859.7 mg/ BS0.7 mg/ General populationGeneral populationLinkalationDNEL InhalationShort term960 mg/m³WorkersLinkalationDNEL InhalationShort term960 mg/m³WorkersSDNEL InhalationDNEL InhalationShort term960 mg/m³WorkersSDNEL InhalationDNEL InhalationLong term1.6 mg/kg Bw/dayGeneral populationSDNEL Long termDNEL InhalationLong term77 mg/m³WorkersSDNEL Long termDNEL InhalationDNEL Bw/dayGeneral populationSDNEL InhalationDNEL InhalationDNEL Bw/dayGeneral WorkersSDNEL InhalationDNEL InhalationSWorkersSDNEL InhalationShort term Inhalation289 mg/m³WorkersSDNEL InhalationDNEL DNEL InhalationSGeneral SSDNEL InhalationDNEL InhalationSGeneral SSDNEL InhalationDNEL DNEL InhalationSGeneral SSDNEL InhalationDNEL InhalationSGeneral SSDNEL InhalationDNEL InhalationSGeneral SSDNEL InhalationDNEL InhalationSGene	Local				DNEL	
InhalationoDNELShort term859.7 mg/ populationGeneral populationDNELShort term859.7 mg/ populationGeneral populationSDNELShort term960 mg/m³WorkersLi inhalationDNELShort term960 mg/m³WorkersSInhalationDNELShort term960 mg/m³WorkersSInhalationDNELShort term960 mg/m³GeneralSDNELShort term960 mg/m³GeneralSInhalationDNELLong term1.6 mg/kgGeneralSDNELLong term17 mg/m³GeneralSDNELLong term77 mg/m³WorkersSInhalationDNELLong term Dermal180 mg/kgGeneralSDNELLong term Dermal180 mg/kgWorkersSDNELShort term289 mg/m³WorkersSDNELShort term289 mg/m³WorkersSDNELLong term Dermal8.2 mg/kgGeneralSDNELLong term Dermal1.6 mg/kgGeneralSDNELLong term1.4 mg/m³GeneralSInhalationDNELLong term Dermal8.2 mg/kgGeneralSDNELLong term208 mg/m³WorkersSInhalationDNELLong term208 mg/m³WorkersSDNELLong term Dermal1 mg/kgGeneralSD						
DNEL InhalationShort term m³859.7 mg/ opulationGeneral populationLi inhalationDNEL InhalationDNEL Short termShort term 960 mg/m³WorkersLi inhalationDNEL InhalationShort term960 mg/m³WorkersLi inhalationDNEL InhalationShort term960 mg/m³WorkersSDNEL InhalationDNEL InhalationLong term1.6 mg/kg populationGeneral populationSDNEL InhalationLong term1.6 mg/kg populationGeneral populationSDNEL InhalationLong term77 mg/m³WorkersSDNEL InhalationLong term108 mg/kg bw/dayGeneral populationSDNEL InhalationDNEL InhalationInma/kg bw/dayGeneral populationSDNEL InhalationDNEL InhalationLong term180 mg/kg bw/dayGeneral populationSDNEL InhalationDNEL InhalationCong term289 mg/m³WorkersSDNEL InhalationDNEL InhalationLong term13.67 mg/ gopulationSDNEL InhalationDNEL InhalationCong term208 mg/m³WorkersSDNEL InhalationDNEL InhalationCong term208 mg/m³WorkersSDNEL InhalationDNEL InhalationCong term208 mg/m³WorkersSDNEL InhalationDNEL InhalationCong term208 mg/m³W	Local	Workers	480 mg/m³		DNEL	
Inhalationm³population GeneralDNELShort term859.7 rg/ InhalationGeneralSDNELShort term960 mg/m³WorkersLInhalationDNELShort term960 mg/m³WorkersSDNELShort term960 mg/m³WorkersSInhalationDNELLong term Oral1.6 mg/kgGeneralSDNELLong term14.8 mg/m³GeneralSDNELLong term77 mg/m³WorkersSInhalationDNELLong term108 mg/kgGeneralSDNELLong term Dermal108 mg/kgGeneralSInhalationDNELLong term Dermal108 mg/kgGeneralSDNELShort term289 mg/m³WorkersSInhalationDNELLong term Dermal8.2 mg/kgGeneralSDNELShort term289 mg/m³WorkersSInhalationDNELLong term Dermal8.2 mg/kgGeneralSDNELLong term Dermal8.2 mg/kgGeneralSInhalationDNELLong term14.3 mg/m³GeneralSDNELLong term104 mg/m³GeneralSInhalationDNELLong term208 mg/m³WorkersSInhalationDNELLong term104 mg/kgGeneralSDNELLong term208 mg/m³WorkersSInhalationDNELLong term<						
DNEL InhalationShort term m³859.7 mg/ populationGeneral populationSReaction mass of ethylbenzene and xyleneDNEL DNELShort term Inhalation960 mg/m³WorkersLDNEL InhalationDNEL DNELCong term Inhalation1.6 mg/kg populationGeneral populationSDNEL Long termLong term Inhalation1.6 mg/kg populationGeneral populationSDNEL InhalationDNEL InhalationLong term Inhalation1.8 mg/m³ PopulationGeneral populationSDNEL InhalationDNEL InhalationLong term Dermal Inhalation108 mg/kg PopulationGeneral populationSDNEL InhalationDNEL InhalationLong term Dermal Inhalation108 mg/kg PopulationGeneral populationSmethyl methacrylateDNEL InhalationLong term Dermal Inhalation8.2 mg/m³ PopulationWorkersSmethyl methacrylateDNEL Iong term Dermal InhalationS.2 mg/kg PopulationGeneral populationSDNEL Iong term InhalationDNEL Iong term Inhalation208 mg/m³ PopulationWorkersSDNEL Iong term InhalationDNEL Iong term208 mg/m³ PopulationWorkersSDNEL Iong term InhalationDNEL Iong term208 mg/m³ PopulationWorkersSDNEL Iong term InhalationDNEL Iong term208 mg/m³ PopulationWorkersSDNEL<	Local				DNEL	
Reaction mass of ethylbenzene and xyleneInhalation DNELm³ Short term Inhalationpopulation WorkersLi InhalationDNELShort term Inhalation960 mg/m³WorkersSDNELShort term Inhalation1.6 mg/kg bw/dayGeneral populationSDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSDNELLong term Inhalation77 mg/m³WorkersSDNELLong term Inhalation77 mg/m³WorkersSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal Inhalation8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation1.6 mg/kg bw/dayGeneral populationSDNELLong term Inhalation1.6 mg/kg bw/dayGeneral populationSDNELLong term Inhalation1.6 mg/kg bw/dayGeneral populationSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation1.5 mg/kg Bo						
DNEL Inhalation DNELShort term Inhalation DNEL960 mg/m³ WorkersWorkersLi NorkersReaction mass of ethylbenzene and xyleneDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSDNELLong term Oral1.8 mg/m³General populationSDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal108 mg/kg bw/dayWorkersSDNELLong term Dermal13.67 mg/ bw/dayWorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Inhalation104 mg/m³General populationLiDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term InhalationDNELLong term InhalationGeneral populationLiDNELLong term Inhalation104 mg/kg bw/dayGeneral populationS <t< td=""><td>Systemic</td><td>-</td><td></td><td></td><td>DNEL</td><td></td></t<>	Systemic	-			DNEL	
Reaction mass of ethylbenzene and xyleneDNELInhalation Short term Long term Oral960 mg/m³ UWrkersWorkersSReaction mass of ethylbenzene and xyleneDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSDNELLong term Inhalation DNELLong term DNEL14.8 mg/m³ populationGeneral populationSDNELLong term Inhalation DNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayWorkersSDNELLong term Dermal Inhalation180 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³ bw/dayWorkersSDNELLong term Dermal Inhalation8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation13.67 mg/ kg bw/dayGeneral populationSDNELLong term Inhalation74.3 mg/m³ General populationGeneral populationLong termScyclohexanoneDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term Inhalation1 mg/kg BowldayGeneral gopulationSDNELLong term Inhalation1 mg/kg BowldayGeneral GeneralSDNELLong term Inhalation1 mg/k						
DNELShort term Inhalation960 mg/m³WorkersSReaction mass of ethylbenzene and xyleneDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSDNELLong term Inhalation14.8 mg/m³General populationSDNELLong term Inhalation77 mg/m³WorkersSDNELLong term Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation180 mg/kg bw/dayGeneral populationSDNELShort term Inhalation289 mg/m³ bw/dayWorkersSDNELLong term Dermal Inhalation13.67 mg/ bw/dayWorkersSDNELLong term Dermal Inhalation104 mg/m³ general populationGeneral populationLong populationLong populationDNELLong term Inhalation104 mg/m³ general populationGeneral populationLong populationLong populationSDNELLong term Inhalation208 mg/m³ gopulationWorkersSDNELLong term Inhalation208 mg/m³ gopulationWorkersSDNELLong term Inhalation104 mg/m³ gopulationSDNELLong term Dermal Inhalation1 mg/kg gopulation <td< td=""><td>Local</td><td>Workers</td><td>960 mg/m³</td><td></td><td>DNEL</td><td></td></td<>	Local	Workers	960 mg/m³		DNEL	
Reaction mass of ethylbenzene and xyleneInhalation						
Reaction mass of ethylbenzene and xyleneDNEL DNELLong term Oral Inhalation1.6 mg/kg bw/dayGeneral populationSDNEL InhalationLong term Inhalation14.8 mg/m³ OpulationGeneral populationSDNEL InhalationLong term Inhalation77 mg/m³WorkersSDNEL InhalationLong term Dermal Bw/day108 mg/kg Bw/dayGeneral populationSDNEL InhalationLong term Dermal Inhalation108 mg/kg Bw/dayGeneral populationSDNEL InhalationLong term Dermal Inhalation108 mg/kg Bw/dayGeneral populationSDNEL InhalationDNEL InhalationSSSDNEL InhalationDNEL InhalationLong term Dermal B.2 mg/m³WorkersSMethyl methacrylateDNEL InhalationLong term Dermal Inhalation8.2 mg/kg Byd/day BONEL InhalationGeneral populationSDNEL InhalationLong term Inhalation104 mg/m³ General DopulationGeneral populationSDNEL InhalationLong term Inhalation208 mg/m³ WorkersWorkersSCyclohexanoneDNEL DNEL InhalationLong term Inhalation104 mg/m³ General populationSDNEL InhalationDNEL InhalationLong term Inhalation108 mg/m³ General populationSDNEL InhalationDNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL 	Systemic	Workers	960 mg/m³		DNEL	
xylenebw/daypopulationDNELLong term14.8 mg/m³General populationSDNELLong term77 mg/m³WorkersSInhalationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal108 mg/kg bw/dayWorkersSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³ bw/dayWorkersSDNELShort term Inhalation289 mg/m³ bw/dayWorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayGeneral populationSDNELLong term Inhalation104 mg/m³ General populationSDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term Inhalation208 mg/m³ WorkersSDNELLong term Inhalation208 mg/m³ WorkersSDNELLong term Inhalation1 mg/kg Beneral populationSDNELShort term Dermal1 mg/kg BordayGeneral SSDNELShort term Oral1 mg/kg Bw/dayGeneral SSDNELLong term Oral1 mg/kg Bw/dayGeneral SSDNELLong term Oral1						
DNELLong term Inhalation14.8 mg/m³ populationGeneral populationSDNELLong term Inhalation77 mg/m³WorkersSDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³WorkersLDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral opulationSDNELLong term Dermal13.67 mg/ WorkersWorkersSDNELLong term Dermal13.67 mg/ WorkersSDNELLong term Inhalation104 mg/m³General populationSDNELLong term Inhalation208 mg/m³WorkersLDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1 mg/kg bw/dayGeneral populationS <td>Systemic</td> <td></td> <td></td> <td>Long term Oral</td> <td>DNEL</td> <td></td>	Systemic			Long term Oral	DNEL	
Inhalation Long term Inhalationpopulation Workerspopulation WorkersDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal108 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal8.2 mg/m³General populationSDNELLong term Dermal104 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term DNEL208 mg/m³WorkersSCyclohexanoneDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/day						xylene
DNELLong term Inhalation77 mg/m³WorkersSDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELCong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayGeneral populationSDNELLong term Inhalation74.3 mg/m³ GeneralGeneral populationSDNELLong term Inhalation104 mg/m³ GeneralGeneral populationLong populationLong termDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term Inhalation208 mg/m³ WorkersSDNELLong term Dermal Inhalation1 mg/kg Bow/dayGeneral populationSDNELLong term Dermal1 mg/kg Bow/dayGeneral populationSDNELLong term Dermal1 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populatio	Systemic		14.8 mg/m³		DNEL	
InhalationInhalationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³WorkersLiDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSmethyl methacrylateDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Inhalation104 mg/m³General populationLi populationLi populationSDNELLong term Inhalation104 mg/m³General populationLi populationLi populationLi populationSDNELLong term Inhalation208 mg/m³WorkersLi populationSDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral <td></td> <td></td> <td></td> <td>Inhalation</td> <td></td> <td></td>				Inhalation		
DNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term inhalation289 mg/m³WorkersLDNELShort term inhalation289 mg/m³WorkersSDNELShort term inhalation289 mg/m³WorkersSDNELCong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ bw/dayWorkersSDNELLong term Dermal13.67 mg/ bw/dayWorkersSDNELLong term Dermal13.67 mg/ bw/dayGeneral populationSDNELLong term inhalation74.3 mg/m³General populationSDNELLong term inhalation208 mg/m³WorkersSDNELLong term inhalation208 mg/m³WorkersSDNELLong term Dermal1 mg/kg bw/dayGeneral populationScyclohexanoneDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELSort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg <br< td=""><td>Systemic</td><td>Workers</td><td>77 mg/m³</td><td>Long term</td><td>DNEL</td><td></td></br<>	Systemic	Workers	77 mg/m³	Long term	DNEL	
bw/daypopulationDNELLong term Dermal180 mg/kgDNELShort term289 mg/m³WorkersSInhalationDNELDNELShort term289 mg/m³WorkersSInhalationDNELDNELShort termInhalationB.2 mg/kgDNELLong term DermalBNELLong term DermalInhalation13.67 mg/WorkersSInhalationNorkersDNELLong termInhalation104 mg/m³GeneralpopulationDNELLong termInhalation104 mg/m³DNELLong termInhalation104 mg/m³ONELLong termInhalation104 mg/m³DNELLong termInhalation104 mg/m³DNELLong termInhalation208 mg/m³WorkersSInhalationDNELLong termInhalation1 mg/kgGeneralSInhalation1 mg/kgDNELLong term DermalInhalation1 mg/kgGeneralSDNELShort term OralInhalation1.5 mg/kgGeneralSDNELLong term OralI.5 mg/kgGeneralSoutianSDNELLong term OralI.5 mg/kgGeneralSoutianSDNELLong term OralI.5 mg/kg <t< td=""><td></td><td></td><td></td><td>Inhalation</td><td></td><td></td></t<>				Inhalation		
DNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³WorkersLiDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Dermal104 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationLo populationDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term DNEL208 mg/m³WorkersSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic	General	108 mg/kg	Long term Dermal	DNEL	
bw/day 289 mg/m³WorkersLi 289 mg/m³methyl methacrylateDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Inhalation74.3 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationLi populationDNELLong term Inhalation208 mg/m³WorkersLi populationDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term DNELShort term Dermal1 mg/kg populationGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS		population				
DNELShort term Inhalation289 mg/m³WorkersLi Workersmethyl methacrylateDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Inhalation74.3 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationLi populationDNELLong term Inhalation104 mg/m³General populationLi populationDNELLong term Inhalation208 mg/m³WorkersLi populationDNELLong term Inhalation208 mg/m³WorkersLi populationDNELLong term Inhalation1 mg/kg Bow/dayGeneral populationSDNELLong term Dermal1 mg/kg Bow/dayGeneral populationSDNELLong term Dermal1 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populationS	Systemic	Workers	180 mg/kg	Long term Dermal	DNEL	
Inhalation DNELDNELInhalation Short term Inhalation289 mg/m³WorkersSmethyl methacrylateDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ bw/dayWorkersSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Inhalation74.3 mg/m³ populationGeneral populationSDNELLong term Inhalation104 mg/m³ populationGeneral populationLong populationLong populationDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term DNEL208 mg/m³ Bhort term DermalWorkersSDNELShort term Dermal1 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populationS			bw/day			
DNELShort term Inhalation289 mg/m³WorkersSmethyl methacrylateDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Inhalation74.3 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationSDNELLong term Inhalation208 mg/m³WorkersLongDNELLong term Inhalation208 mg/m³WorkersLongDNELLong term Inhalation208 mg/m³WorkersSDNELLong term DNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Local	Workers	289 mg/m <sup>3</sup>	Short term	DNEL	
methyl methacrylateInhalation0DNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term74.3 mg/m³General populationSDNELLong term104 mg/m³General populationLong termDNELLong term104 mg/m³General populationLong termDNELLong term208 mg/m³WorkersLong termDNELLong term208 mg/m³WorkersSInhalationDNELLong term208 mg/m³WorkersSDNELLong term208 mg/m³WorkersSInhalationDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS				Inhalation		
methyl methacrylateDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term74.3 mg/m³General populationSDNELLong term104 mg/m³General populationSDNELLong term104 mg/m³General populationLong termDNELLong term208 mg/m³WorkersLong termDNELLong term208 mg/m³WorkersLong termDNELLong term208 mg/m³WorkersSInhalationDNELLong term208 mg/m³WorkersSDNELLong term208 mg/m³WorkersSInhalationDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic	Workers	289 mg/m <sup>3</sup>	Short term	DNEL	
DNELLong term Dermalbw/daypopulationDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term104 mg/m³General populationSInhalationDNELLong term104 mg/m³General populationLong populationDNELLong term208 mg/m³WorkersLong populationDNELLong term208 mg/m³WorkersLong populationDNELLong term208 mg/m³WorkersSInhalationDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS				Inhalation		
DNELLong term Dermalbw/day 13.67 mg/ kg bw/daypopulation WorkersSDNELLong term74.3 mg/m³General populationSDNELLong term104 mg/m³General populationLong termDNELLong term104 mg/m³General populationLong termDNELLong term208 mg/m³WorkersLong termDNELLong term208 mg/m³WorkersLong termDNELLong term208 mg/m³WorkersSInhalationDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic	General		Long term Dermal	DNEL	methyl methacrylate
cyclohexanoneDNELLong term Inhalationkg bw/day 74.3 mg/m³General populationS populationDNELLong term Inhalation104 mg/m³General populationLong termDNELLong term Inhalation208 mg/m³WorkersLong termDNELLong term Inhalation208 mg/m³WorkersS populationDNELLong term Inhalation208 mg/m³WorkersS populationDNELLong term Inhalation208 mg/m³WorkersS populationDNELLong term Dermal1 mg/kgGeneral populationS populationDNELLong term Dermal1 mg/kgGeneral populationS populationDNELShort term Oral1.5 mg/kgGeneral populationS populationDNELLong term Oral1.5 mg/kgGeneral populationS population		population	bw/day			
DNELLong term Inhalation74.3 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationLong termDNELLong term Inhalation208 mg/m³WorkersLong termDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation1 mg/kgGeneral populationSDNELShort term Dermal1 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationS	Systemic	Workers		Long term Dermal	DNEL	
InhalationpopulationDNELLong term104 mg/m³General populationDNELLong term208 mg/m³WorkersLongDNELLong term208 mg/m³WorkersLongDNELLong term208 mg/m³WorkersSInhalationDNELShort term Dermal1 mg/kgGeneral populationSDNELShort term Dermal1 mg/kgGeneral populationSDNELLong term Dermal1 mg/kgGeneral populationSDNELLong term Dermal1.5 mg/kgGeneral populationSDNELShort term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationS						
DNELLong term Inhalation104 mg/m³General populationLong term populationDNELLong term Inhalation208 mg/m³WorkersLong termDNELLong term Inhalation208 mg/m³WorkersSCyclohexanoneDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic		74.3 mg/m <sup>3</sup>		DNEL	
Inhalation Long term Inhalation208 mg/m³population WorkersDNELLong term Inhalation208 mg/m³WorkersLong WorkersDNELLong term Inhalation208 mg/m³WorkersSONELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS						
DNELLong term Inhalation208 mg/m³WorkersLongDNELLong term Inhalation208 mg/m³WorkersS208 mg/m³WorkersSNELLong term Inhalation208 mg/m³WorkersSDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Local		104 mg/m³		DNEL	
cyclohexanone DNEL Inhalation Long term 208 mg/m <sup>3</sup> Workers S Inhalation DNEL Short term Dermal 1 mg/kg General S bw/day population DNEL Long term Dermal 1 mg/kg General S bw/day population DNEL Short term Oral 1.5 mg/kg General S bw/day population S DNEL Long term Oral 1.5 mg/kg General S bw/day population S bw/day population S bw/day population S bw/day population S bw/day population S bw/day Seneral S						
cyclohexanoneDNELLong term Inhalation208 mg/m³WorkersScyclohexanoneDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Local	Workers	208 mg/m <sup>3</sup>	-	DNEL	
cyclohexanoneInhalationI mg/kg bw/dayGeneral populationSDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS						
cyclohexanoneDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kgGeneral bw/daySDNELShort term Oral1.5 mg/kgGeneral populationSDNELShort term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationS	Systemic	Workers	208 mg/m <sup>3</sup>		DNEL	
DNELLong term Dermalbw/daypopulationDNELLong term Dermal1 mg/kgGeneralSbw/daypopulation1.5 mg/kgGeneralSbw/dayDNELShort term Oral1.5 mg/kgGeneralSbw/daypopulation1.5 mg/kgGeneralSbw/daypopulationSbw/daypopulationbw/daypopulationSbw/daypopulationbw/daypopulationSbw/daypopulation						
DNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic			Short term Dermal	DNEL	cyclohexanone
DNELShort term Oralbw/daypopulationDNELShort term Oral1.5 mg/kgGeneralSbw/daypopulation1.5 mg/kgGeneralSbw/daybw/daypopulationSbw/daypopulationSbw/daypopulationSbw/daypopulationSbw/daypopulationS						
DNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic			Long term Dermal	DNEL	
DNEL Long term Oral bw/day population 1.5 mg/kg General S bw/day population						
DNELLong term Oral1.5 mg/kgGeneralSbw/daypopulation	Systemic		1.5 mg/kg	Short term Oral	DNEL	
DNEL     Long term Oral     1.5 mg/kg     General     S       bw/day     population			bw/day			
bw/day population	Systemic		1.5 mg/kg	Long term Oral	DNEL	
e of issue/Date of revision :1-11-2022 Version :1.01		population		-		
e of issue/Date of revision : 1-11-2022 Version : 1.01	<u> </u>				<u> </u>	
		: 1.01				
e of previous issue : 1-10-2022 8/19	AkzoNo		8/19		-2022	e of previous issue : 1-1



<b>SECTION 8: Exposure cont</b>	rols/p	ersonal prote	ction		
	DNEL	Short term Dermal	4 mg/kg bw/day	Workers	Systemic
	DNEL	Long term Dermal	4 mg/kg bw/day	Workers	Systemic
	DNEL	Long term Inhalation	10 mg/m³	General population	Systemic
	DNEL	Long term Inhalation	20 mg/m³	General population	Local
	DNEL	Short term Inhalation	20 mg/m³	General population	Systemic
	DNEL	Short term Inhalation	40 mg/m³	General population	Local
	DNEL	Long term Inhalation	40 mg/m³	Workers	Local
	DNEL	Long term Inhalation	40 mg/m³	Workers	Systemic
	DNEL	Short term Inhalation	80 mg/m³	Workers	Local
	DNEL	Short term Inhalation	80 mg/m³	Workers	Systemic

#### **PNECs**

No PNECs available.

8.2 Exposure controls						
Appropriate engineering controls	ventilation or other en contaminants below a controls also need to	Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapor or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.				
Individual protection meas	ures					
Hygiene measures	before eating, smokin Appropriate technique Wash contaminated o	s and face thoroughly after handling g and using the lavatory and at the eres should be used to remove potentia dothing before reusing. Ensure that eres base to the workstation location.	nd of the working period. Ily contaminated clothing.			
Eye/face protection	assessment indicates gases or dusts. If cor	lying with an approved standard shou this is necessary to avoid exposure f ntact is possible, the following protect nt indicates a higher degree of protec	to liquid splashes, mists, ion should be worn,			
Skin protection						
Hand protection	be worn at all times w this is necessary. Co check during use that should be noted that different for different g	npervious gloves complying with an a hen handling chemical products if a r nsidering the parameters specified by the gloves are still retaining their pro he time to breakthrough for any glove glove manufacturers. In the case of r ne protection time of the gloves cann	y the glove manufacturer, tective properties. It material may be nixtures, consisting of			
	protection class of 6 ( recommended. Reco When only brief conta (breakthrough time > Recommended glove	equently repeated contact may occur breakthrough time >480 minutes acc mmended gloves: Viton ® or Nitrile, t ict is expected, a glove with protectio 30 minutes according to EN374) is re- s: Nitrile, thickness ≥ 0.12 mm. aced regularly and if there is any sign	ording to EN374) is hickness ≥ 0.38 mm. n class of 2 or higher commended.			
Date of issue/Date of revision	: 1-11-2022	Version : 1.01				
Date of previous issue	: 1-10-2022	9/19	AkzoNobel			

### **SECTION 8: Exposure controls/personal protection**

		The performance or effectiveness of the glove may be reduced by physical/ chemical damage and poor maintenance.
		The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.
Body protection	:	Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.
Other skin protection	:	Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	:	Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
Environmental exposure controls	:	Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

## **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

#### **Appearance**

<u>Appearance</u>		
Physical state	:	Liquid.
Color	:	White.
Odor	:	Characteristic.
Odor threshold	:	Not available.
рН	:	Not available.
Melting point/freezing point	:	Not available.
Initial boiling point and boiling range	:	Not available.
Flash point	:	Closed cup: 28°C
Evaporation rate	:	Not available.
Flammability (solid, gas)	:	Not available.
Upper/lower flammability or explosive limits	:	Not available.
Vapor pressure	:	Not available.
Vapor density	:	Highest known value: 4.6 (Air = 1) (2-methoxy-1-methylethyl acetate). Weighted average: 3.99 (Air = 1)
Density	:	1.402 g/cm³
Solubility(ies)	:	Insoluble in the following materials: cold water.
Partition coefficient: n-octanol/ water	:	Not available.
Auto-ignition temperature	:	Not available.
Decomposition temperature	:	Not available.
Viscosity	:	Kinematic (room temperature): 7.85 cm²/s Kinematic (40°C): 1.01 cm²/s

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	10/19	AkzoNobel

## **SECTION 10: Stability and reactivity**

10.1 Poactivity	: No specific test data related to reactivity available for this product or its ingredients.
10.1 Reactivity	
10.2 Chemical stability	: The product is stable.
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld,
	braze, solder, drill, grind or expose containers to heat or sources of ignition.
10.5 Incompatible materials	<ul> <li>Reactive or incompatible with the following materials: oxidizing materials</li> </ul>
10.6 Hazardous	: Under normal conditions of storage and use, hazardous decomposition products
decomposition products	should not be produced.

## **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

#### Acute toxicity

LC5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD	<ul> <li>0 Inhalation Gas.</li> <li>0 Inhalation Vapor</li> <li>0 Dermal</li> <li>0 Intraperitoneal</li> <li>0 Oral</li> <li>0 Oral</li> <li>0 Oral</li> <li>0 Oral</li> <li>0 Oral</li> <li>0 Inhalation Gas.</li> <li>0 Inhalation Vapor</li> <li>0 Inhalation Vapor</li> <li>0 Dermal</li> <li>0 Intraperitoneal</li> <li>0 Intraperitoneal</li> <li>0 Intraperitoneal</li> <li>0 Oral</li> <li>0 Oral</li> <li>0 Oral</li> <li>0 Oral</li> <li>0 Dermal</li> <li>0 Dermal</li> <li>0 Intraperitoneal</li> <li>0 Oral</li> </ul>	Rat Mouse Rabbit Mouse Guinea pig Mouse Ratbit Rat Rat Rat Rabbit Guinea pig Mouse Rat Guinea pig Mouse Rat	390 ppm 6 g/m <sup>3</sup> >17600 mg/kg 1230 mg/kg 4700 mg/kg 6 g/kg 3200 mg/kg 10768 mg/kg 5000 ppm 18500 mg/m <sup>3</sup> >5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg 8700 mg/kg	4 hours 2 hours - - - 4 hours 2 hours 4 hours - - - - - - - - - - - - -
cyclohexanone LC5	<ul> <li>Dermal</li> <li>Dermal</li> <li>Intraperitoneal</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Inhalation Gas.</li> <li>Inhalation Vapor</li> <li>Inhalation Vapor</li> <li>Dermal</li> <li>Intraperitoneal</li> <li>Intraperitoneal</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> </ul>	Rabbit Mouse Guinea pig Mouse Rabbit Rat Rat Mouse Rat Guinea pig Mouse Rat Guinea pig Mouse Rat Guinea pig Mouse Rabbit	6 g/m <sup>3</sup> >17600 mg/kg 1230 mg/kg 4700 mg/kg 6 g/kg 3200 mg/kg 10768 mg/kg 5000 ppm 18500 mg/m <sup>3</sup> 78000 mg/m <sup>3</sup> >5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	- - - - - 4 hours 2 hours
LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 ethylbenzene and xylene methyl methacrylate LC5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD	<ul> <li>Dermal</li> <li>Dermal</li> <li>Intraperitoneal</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Inhalation Gas.</li> <li>Inhalation Vapor</li> <li>Inhalation Vapor</li> <li>Dermal</li> <li>Intraperitoneal</li> <li>Intraperitoneal</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> </ul>	Mouse Guinea pig Mouse Rabbit Rat Rat Mouse Rat Guinea pig Mouse Rat Guinea pig Mouse Rat Guinea pig Mouse Rabbit	>17600 mg/kg 1230 mg/kg 4700 mg/kg 6 g/kg 3200 mg/kg 10768 mg/kg 5000 ppm 18500 mg/m <sup>3</sup> 78000 mg/m <sup>3</sup> >5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	2 hours
cyclohexanone	<ul> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Inhalation Gas.</li> <li>Inhalation Vapor</li> <li>Inhalation Vapor</li> <li>Dermal</li> <li>Intraperitoneal</li> <li>Intraperitoneal</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> </ul>	Guinea pig Mouse Rabbit Rat Rat Mouse Rat Guinea pig Mouse Rat Guinea pig Mouse Rat Guinea pig Mouse Rabbit	1230 mg/kg 4700 mg/kg 6 g/kg 3200 mg/kg 10768 mg/kg 5000 ppm 18500 mg/m <sup>3</sup> 78000 mg/m <sup>3</sup> >5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	2 hours
cyclohexanone	<ul> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Inhalation Gas.</li> <li>Inhalation Vapor</li> <li>Inhalation Vapor</li> <li>Dermal</li> <li>Intraperitoneal</li> <li>Intraperitoneal</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> </ul>	Mouse Rabbit Rat Rat Mouse Rat Rabbit Guinea pig Mouse Rat Guinea pig Mouse Rat Guinea pig Mouse Rabbit	4700 mg/kg 6 g/kg 3200 mg/kg 10768 mg/kg 5000 ppm 18500 mg/m <sup>3</sup> 78000 mg/m <sup>3</sup> >5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	2 hours
cyclohexanone	<ul> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Inhalation Gas.</li> <li>Inhalation Vapor</li> <li>Inhalation Vapor</li> <li>Dermal</li> <li>Intraperitoneal</li> <li>Intraperitoneal</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> </ul>	Mouse Rabbit Rat Rat Mouse Rat Rabbit Guinea pig Mouse Rat Guinea pig Mouse Rat Guinea pig Mouse Rabbit	6 g/kg 3200 mg/kg 10768 mg/kg 5000 ppm 18500 mg/m <sup>3</sup> 78000 mg/m <sup>3</sup> >5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	2 hours
Reaction mass of LC5 ethylbenzene and xylene methyl methacrylate LC5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD	<ul> <li>Oral</li> <li>Inhalation Gas.</li> <li>Inhalation Vapor</li> <li>Inhalation Vapor</li> <li>Inhalation Vapor</li> <li>Dermal</li> <li>Intraperitoneal</li> <li>Intraperitoneal</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> </ul>	Rat Rat Mouse Rat Rabbit Guinea pig Mouse Rat Guinea pig Mouse Rabbit	3200 mg/kg 10768 mg/kg 5000 ppm 18500 mg/m <sup>3</sup> 78000 mg/m <sup>3</sup> >5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	2 hours
Reaction mass of LC5 ethylbenzene and xylene methyl methacrylate LC5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD	<ul> <li>Oral</li> <li>Inhalation Gas.</li> <li>Inhalation Vapor</li> <li>Inhalation Vapor</li> <li>Inhalation Vapor</li> <li>Dermal</li> <li>Intraperitoneal</li> <li>Intraperitoneal</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> <li>Oral</li> </ul>	Rat Mouse Rat Rabbit Guinea pig Mouse Rat Guinea pig Mouse Rabbit	10768 mg/kg 5000 ppm 18500 mg/m <sup>3</sup> 78000 mg/m <sup>3</sup> >5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	2 hours
ethylbenzene and xylene methyl methacrylate LC5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD	<ul> <li>0 Inhalation Vapor</li> <li>0 Inhalation Vapor</li> <li>0 Dermal</li> <li>0 Intraperitoneal</li> <li>0 Intraperitoneal</li> <li>0 Intraperitoneal</li> <li>0 Oral</li> <li>0 Oral</li> <li>0 Oral</li> <li>0 Oral</li> </ul>	Mouse Rat Rabbit Guinea pig Mouse Rat Guinea pig Mouse Rabbit	5000 ppm 18500 mg/m <sup>3</sup> 78000 mg/m <sup>3</sup> >5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	2 hours
methyl methacrylate LC5 LC5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD	0 Inhalation Vapor 0 Dermal 0 Intraperitoneal 0 Intraperitoneal 0 Intraperitoneal 0 Oral 0 Oral 0 Oral	Rat Rabbit Guinea pig Mouse Rat Guinea pig Mouse Rabbit	78000 mg/m <sup>3</sup> >5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	
LC5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD	0 Inhalation Vapor 0 Dermal 0 Intraperitoneal 0 Intraperitoneal 0 Intraperitoneal 0 Oral 0 Oral 0 Oral	Rabbit Guinea pig Mouse Rat Guinea pig Mouse Rabbit	78000 mg/m <sup>3</sup> >5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	
LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5	0 Dermal 0 Intraperitoneal 0 Intraperitoneal 0 Intraperitoneal 0 Oral 0 Oral 0 Oral	Rabbit Guinea pig Mouse Rat Guinea pig Mouse Rabbit	>5 g/kg 1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	-
LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5	0 Intraperitoneal 0 Intraperitoneal 0 Intraperitoneal 0 Oral 0 Oral 0 Oral	Guinea pig Mouse Rat Guinea pig Mouse Rabbit	1890 mg/kg 945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	- - - -
LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5	0 Intraperitoneal 0 Intraperitoneal 0 Oral 0 Oral 0 Oral	Mouse Rat Guinea pig Mouse Rabbit	945 mg/kg 1328 mg/kg 5954 mg/kg 3625 mg/kg	- - -
LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5	0 Intraperitoneal 0 Oral 0 Oral 0 Oral	Rat Guinea pig Mouse Rabbit	1328 mg/kg 5954 mg/kg 3625 mg/kg	- - -
LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5	0 Oral 0 Oral 0 Oral	Guinea pig Mouse Rabbit	5954 mg/kg 3625 mg/kg	-
LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5	0 Oral 0 Oral	Mouse Rabbit	3625 mg/kg	-
LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5	0 Oral	Rabbit		_
LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5 LD5				
LD5 LD5 cyclohexanone LC5 LD5 LD5 LD5 LD5		Rat	7872 mg/kg	-
LD5 LD5 cyclohexanone LC5 LD5 LD5 LD5	0 Subcutaneous	Guinea pig	5954 mg/kg	-
cyclohexanone LC5 LD5 LD5 LD5 LD5 LD5	0 Subcutaneous	Mouse	5954 mg/kg	-
cyclohexanone LC5 LD5 LD5 LD5 LD5	0 Subcutaneous	Rat	7088 mg/kg	-
LD5 LD5 LD5	0 Inhalation Gas.	Rat	8000 ppm	4 hours
LD5 LD5	0 Dermal	Rabbit	1 mL/kg	-
LD5	0 Intraperitoneal	Guinea pig	930 mg/kg	-
	0 Intraperitoneal	Mouse	1230 mg/kg	-
	0 Intraperitoneal	Mouse	1230 mg/kg	-
	0 Intraperitoneal	Rabbit	1540 mg/kg	-
	0 Intraperitoneal	Rabbit	1540 mg/kg	-
	0 Intraperitoneal	Rat	1130 mg/kg	-
	0 Intraperitoneal	Rat	1130 mg/kg	-
	0 Oral	Mouse	1400 mg/kg	-
	0 Oral	Rat	1800 mg/kg	-
	0 Oral	Rat	1620 uL/kg	-
	0 Subcutaneous	Rat	2170 mg/kg	-
e of issue/Date of revision :1				•

Date of previous issue

11/19



### **SECTION 11: Toxicological information**

#### **Conclusion/Summary** : Not available.

Irritation/Corrosion	
Product/ingredient	name Result
-butyl acetate	Eyes - Moderate irri

Product/ingredient name	Result	Species	Score	Exposure	Observation
-butyl acetate	Eyes - Moderate irritant	Rabbit	-	100 mg	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
				mg	
Reaction mass of ethylbenzene and xylene	Eyes - Mild irritant	Rabbit	-	87 mg	-
	Eyes - Severe irritant	Rabbit	-	24 hours 5	-
				mg	
	Skin - Mild irritant	Rat	-	8 hours 60 UI	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
				mg	
	Skin - Moderate irritant	Rabbit	-	100 %	-
cyclohexanone	Eyes - Severe irritant	Rabbit	-	24 hours 250	-
				ug	
	Eyes - Severe irritant	Rabbit	-	20 mg	-
	Skin - Mild irritant	Rabbit	-	500 mg	-
Conclusion/Summary	: Not available.		1	•	

: Not available.
: Not available.

#### Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
r butyl acetate Reaction mass of ethylbenzene and xylene	Category 3 Category 3	-	Narcotic effects Respiratory tract irritation
2-methoxy-1-methylethyl acetate methyl methacrylate	Category 3 Category 3	-	Narcotic effects Respiratory tract irritation

#### Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Reaction mass of ethylbenzene and xylene	Category 2	-	-

#### Aspiration hazard

Product/ingredient name	Result
Reaction mass of ethylbenzene and xylene Hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, <2% aromatics	ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1

#### Information on the likely : Not available. routes of exposure



## **SECTION 11: Toxicological information**

SECTION 11: Toxico	logical information
Potential acute health effect	2
Eye contact	: Causes serious eye irritation.
Inhalation	: Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness.
Skin contact	: Causes skin irritation.
Ingestion	: Can cause central nervous system (CNS) depression.
Symptoms related to the phy	sical, chemical and toxicological characteristics
Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.
Delayed and immediate effect	ts and also chronic effects from short and long term exposure
Short term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Long term exposure Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Potential chronic health eff Not available.	
Conclusion/Summary	: Not available.
General	<ul><li>May cause damage to organs through prolonged or repeated exposure.</li></ul>
Carcinogenicity	<ul> <li>No known significant effects or critical hazards.</li> </ul>
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.
Other information	: Not available.

## **SECTION 12: Ecological information**

#### 12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is not classified as hazardous to the environment, but contains substance(s) hazardous to the environment. See section 3 for details.

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	13/19	AkzoNobel

## **SECTION 12: Ecological information**

Product/ingredient name	Result	Species	Exposure		
n-butyl acetate	Acute LC50 32 mg/l Marine water	Crustaceans - Artemia salina	48 hours		
	Acute LC50 100000 µg/l Fresh water	Fish - Lepomis macrochirus	96 hours		
	Acute LC50 18000 µg/l Fresh water	Fish - Pimephales promelas	96 hours		
	Acute LC50 185000 µg/l Marine water	Fish - Menidia beryllina	96 hours		
	Acute LC50 62000 µg/l Fresh water	Fish - Danio rerio	96 hours		
Reaction mass of ethylbenzene and xylene	Acute LC50 13400 µg/l Fresh water	Fish - Pimephales promelas	96 hours		
methyl methacrylate	Acute LC50 191000 µg/l Fresh water	Fish - Lepomis macrochirus - Juvenile (Fledgling, Hatchling, Weanling)	96 hours		
	Acute LC50 159100 µg/l Fresh water	Fish - Pimephales promelas	96 hours		
	Acute LC50 160200 µg/l Fresh water	Fish - Pimephales promelas	96 hours		
	Acute LC50 150000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours		
	Acute LC50 130000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours		
cyclohexanone	Acute EC50 32.9 mg/l Fresh water	Algae - Chlamydomonas reinhardtii - Exponential growth phase	72 hours		
	Acute LC50 630000 µg/l Fresh water	Fish - Pimephales promelas	96 hours		
	Acute LC50 527000 µg/l Fresh water	Fish - Pimephales promelas	96 hours		
	Acute LC50 732000 µg/l Fresh water	Fish - Pimephales promelas	96 hours		

Conclusion/Summary

: Not available.

#### 12.2 Persistence and degradability

**Conclusion/Summary** : Not available.

#### 12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
-butyl acetate	2.3	-	low
Reaction mass of ethylbenzene and xylene	3.12	8.1 to 25.9	low
2-methoxy-1-methylethyl acetate	1.2	-	low
methyl methacrylate cyclohexanone	1.38 0.86	-	low low

#### 12.4 Mobility in soil

Soil/water partition coefficient (K <sub>oc</sub> )	: Not available.
Mobility	: Not available.

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.



## **SECTION 13: Disposal considerations**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 13.1 Waste treatment methods

<u>Product</u>	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non- recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.
Disposal considerations	: Do not allow to enter drains or watercourses. Dispose of according to all federal, state and local applicable regulations. If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned. For further information, contact your local waste authority.

#### European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

Waste code	Waste designation	
EWC 08 01 11*	waste paint and varnish containing organic solvents or other hazardous substances	
Packaging		
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.	
Disposal considerations	<ul> <li>Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions.</li> </ul>	
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.	

## **SECTION 14: Transport information**

	ADR/RID	IMDG		ΙΑΤΑ
14.1 UN number	UN1263	UN1263	UN1263	
14.2 UN proper shipping name	PAINT	PAINT	PAINT	
14.3 Transport hazard class(es)	3	3	3	
14.4 Packing group			111	
Date of issue/Date of rev	rision : 1-11-2022	Versio	<b>n</b> :1.01	
Date of previous issue	: 1-10-2022	15/19		AkzoNobel

SECTION 14: Transport information						
14.5 Environmental hazards	No.			No.		No.
Additional information	tion					
ADR/RID		:		50 L according to 2.2		d is not subject to regulation in
IMDG		:	Emergency sched	l <b>ules</b> F-E, _S-E_		d is not subject to regulation in
14.6 Special precau user	tions for	:	<b>Transport within user's premises:</b> always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.			
14.7 Transport in bu according to IMO instruments	ılk	:	: Not applicable.			
SECTION 15: Regulatory information						
15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture						
EU Regulation (EC) No. 1907/2006 (REACH)						
Annex XIV - List of substances subject to authorization						
<u>Annex XIV</u>						
None of the comp	None of the components are listed.					

#### Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions : Not applicable. on the manufacture, placing on the market

and use of certain dangerous substances, mixtures and articles

**Other EU regulations** 

VOC : The provisions of Directive 2004/42/EC on VOC apply to this product. Refer to the product label and/or technical data sheet for further information. VOC for Ready-for-Use : Not applicable. Mixture : Not listed Industrial emissions (integrated pollution prevention and control) -Air Industrial emissions : Not listed (integrated pollution prevention and control) -Water Ozone depleting substances (1005/2009/EU) Not listed.

#### Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

#### **Seveso Directive**

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	16/19	AkzoNobel

SECTION 15: Reg	ulatory information
This product is controlle	d under the Seveso Directive.
Danger criteria	
Category	
P5c	
National regulations	
Industrial use	: The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.
International regulation	<u>s</u>
Chemical Weapon Conv	vention List Schedules I, II & III Chemicals
Not listed.	
Montreal Protocol	
Not listed.	
Stockholm Convention	on Persistent Organic Pollutants
Not listed.	
Rotterdam Convention	on Prior Informed Consent (PIC)
Not listed.	
UNECE Aarhus Protoco	I on POPs and Heavy Metals
Not listed.	
Inventory list	
Europe	: Not determined.
15.2 Chemical Safety Assessment	: No Chemical Safety Assessment has been carried out.
SECTION 16: Othe	er information
Indicates information the second s	nat has changed from previously issued version.
Abbreviations and acronyms	: ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.
1272/2008]
DMEL = Derived Minimal Effect Level
DNEL = Derived No Effect Level
EUH statement = CLP-specific Hazard statement
N/A = Not available
PBT = Persistent, Bioaccumulative and Toxic
PNEC = Predicted No Effect Concentration
RRN = REACH Registration Number
SGG = Segregation Group
vPvB = Very Persistent and Very Bioaccumulative

#### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Flam. Liq. 3, H226	On basis of test data
Skin Irrit. 2, H315	Calculation method
Eye Irrit. 2, H319	Calculation method
STOT SE 3, H336	Calculation method
STOT RE 2, H373	Calculation method

#### Full text of abbreviated H statements

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	17/19	AkzoNobel

SECTION 16: Other information		
<b>⊮</b> 225		Highly flammable liquid and vapor.
H226		Flammable liquid and vapor.
H304		May be fatal if swallowed and enters airways.
H312		Harmful in contact with skin.
H315		Causes skin irritation.
H317		May cause an allergic skin reaction.
H319		Causes serious eye irritation.
H332		Harmful if inhaled.
H335		May cause respiratory irritation.
H336		May cause drowsiness or dizziness.
H373		May cause damage to organs through prolonged or repeated
		exposure.
H412		Harmful to aquatic life with long lasting effects.
EUH066		Repeated exposure may cause skin dryness or cracking.
Full text of classifications [	<u>CLP/GHS]</u>	
Acute Tox. 4		ACUTE TOXICITY - Category 4
Aquatic Chronic 3		AQUATIC HAZARD (LONG-TERM) - Category 3
Asp. Tox. 1		ASPIRATION HAZARD - Category 1
Eye Irrit. 2		SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2
Flam. Liq. 2		FLAMMABLE LIQUIDS - Category 2
Flam. Liq. 3		FLAMMABLE LIQUIDS - Category 3
Skin Irrit. 2		SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1		SKIN SENSITIZATION - Category 1
STOT RE 2		SPECIFIC TARGET ORGAN TOXICITY (REPEATED
		EXPOSURE) - Category 2
STOT SE 3		SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) -
		Category 3
Date of printing	: 1 November 202	22
Date of issue/ Date of revision	: 1 November 202	22
Date of previous issue	: 1 October 2022	
Version	: 1.01	
Unique ID	:	
Notico to reador		

#### Notice to reader

FOR PROFESSIONAL USE ONLY

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.



